EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial

Haidar M Al-Khazali, Rune H Christensen, David W Dodick, Basit Ali Chaudhry, Faisal Mohammad Amin, Rami Burstein iD, Håkan Ashina iD

Brain · 04.04.2024 · 147 (4) · 1312-1320

DOI: 10.1093/brain/awad367 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain, online erschienen am 21.10.2023. Verfasst von Haidar M Al-Khazali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Post-Traumatic Headache. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University Hospital-Rigshospitalet, Hartmann Foundation, Lundbeck Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), known for its role in migraine pathogenesis, has been identified as a novel drug target. Given the clinical parallels between post-traumatic headache (PTH) and migraine, we explored the possible role of PACAP-38 in the pathogenesis of PTH. To this end, we conducted a randomized, double-blind, placebo-controlled, two-way crossover trial involving adult participants diagnosed with persistent PTH resulting from mild traumatic brain injury. Participants were randomly assigned to receive a 20-min continuous intravenous infusion of either PACAP-38 (10 pmol/kg/min) or placebo (isotonic saline) on two separate experimental days, with a 1-week washout period in between. The primary outcome was the difference in incidence of migraine-like headache between PACAP-38 and placebo during a 12-h observational period post-infusion. The secondary outcome was the difference in the area under the curve (AUC) for baseline-corrected median headache intensity scores during the same 12-h observational period. Of 49 individuals assessed for eligibility, 21 were enrolled and completed the trial. The participants had a mean age of 35.2 years, and 16 (76%) were female. Most [19 of 21 (90%)] had a migraine-like phenotype. During the 12-h observational period, 20 of 21 (95%) participants developed migraine-like headache after intravenous infusion of PACAP-38, compared with two (10%) participants after placebo (P < 0.001). Furthermore, the baseline-corrected AUC values for median headache intensity scores during the 12-h observational period was higher after PACAP-38 than placebo (P < 0.001). These compelling results demonstrate that PACAP-38 is potent inducer of migraine-like headache in people with persistent PTH. Thus, targeting PACAP-38 signalling might be a promising avenue for the treatment of PTH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPost-Traumatic HeadacheAdultFemaleHumansMaleDouble-Blind MethodPituitary Adenylate Cyclase-Activating Polypeptide

Stichwörter der Autor:innen

concussionheadache disordersmigrainepathophysiologytrigeminovascular system

Substanzen

Pituitary Adenylate Cyclase-Activating Polypeptide

Autor:innen und Institutionen

  • Harvard Medical School, Boston, MA 02115, USA.
  • Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen 2600, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark.
  • Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA.
  • Department of Brain and Spinal Cord Injury, Copenhagen University Hospital-Rigshospitalet, Copenhagen 2600, Denmark.

ORCID-Profile: Rami Burstein, Håkan Ashina

Förderung

  • Copenhagen University Hospital-Rigshospitalet
  • Hartmann Foundation
  • Lundbeck Foundation
  • Copenhagen University Hospital—Rigshospitalet

Zitieren

APA

Al-Khazali, H. M., Christensen, R. H., Dodick, D. W., Chaudhry, B. A., Amin, F. M., Burstein, R., & Ashina, H. (2024). Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial. Brain, 147(4), 1312-1320. https://doi.org/10.1093/brain/awad367

Vancouver

Al-Khazali HM, Christensen RH, Dodick DW, Chaudhry BA, Amin FM, Burstein R, et al. Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial. Brain. 2024;147(4):1312-1320. doi:10.1093/brain/awad367

BibTeX
@article{AlKhazali2024,
  author = {Al-Khazali, Haidar M and Christensen, Rune H and Dodick, David W and Chaudhry, Basit Ali and Amin, Faisal Mohammad and Burstein, Rami and Ashina, Håkan},
  title = {Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {4},
  pages = {1312--1320},
  doi = {10.1093/brain/awad367}
}
Kostenlos starten →